<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574795</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-3003</org_study_id>
    <nct_id>NCT00574795</nct_id>
  </id_info>
  <brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants</brief_title>
  <official_title>A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the
      13-valent pneumococcal conjugate vaccine (13vPnC) in infants of Japanese descent.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series</measure>
    <time_frame>one month after 3-dose infant series (at 7 months of age)</time_frame>
    <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the 3-Dose Infant Series</measure>
    <time_frame>one mone month after 3-dose infant series (at 7 months of age)</time_frame>
    <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose</measure>
    <time_frame>one month after the toddler dose (at 12 - 15 months of age)</time_frame>
    <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose</measure>
    <time_frame>one month after the toddler dose (at 12-15 months of age)</time_frame>
    <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <enrollment type="Actual">193</enrollment>
  <condition>Vaccines, Pneumococcal Conjugate Vaccine</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13vPnC</intervention_name>
    <description>&quot;First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age&quot;</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 2 to 6 month-old infant

          -  Available for entire study period

        Exclusion Criteria:

          -  Previous vaccination with licensed or investigational pneumococcal vaccine.

          -  Previous anaphylactic reaction to any vaccine or vaccine-related component.

          -  Contraindication to vaccination with a pneumococcal conjugate vaccine.

          -  Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate any type of injection.

          -  Known or suspected immune deficiency or suppression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyohashi-shi</city>
        <state>Aichi</state>
        <zip>441-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <zip>261-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama-shi</city>
        <state>Ehime</state>
        <zip>790-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>811-1394</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>813-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>814-0162</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>819-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebaru-shi</city>
        <state>Fukuoka</state>
        <zip>819-1138</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asahikawa-shi</city>
        <state>Hokkaido</state>
        <zip>078-8211</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>006-0831</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>062-0931</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>063-0831</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>240-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokosuka-shi</city>
        <state>Kanagawa</state>
        <zip>238-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nangoku-shi</city>
        <state>Kochi</state>
        <zip>783-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ise-shi</city>
        <state>Mie</state>
        <zip>516-0805</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsu-shi</city>
        <state>Mie</state>
        <zip>514-025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokkaichi-shi</city>
        <state>Mie</state>
        <zip>510-8561</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <zip>701-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>154-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>154-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2007</study_first_posted>
  <results_first_submitted>March 26, 2010</results_first_submitted>
  <results_first_submitted_qc>June 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2012</results_first_posted>
  <last_update_submitted>June 28, 2012</last_update_submitted>
  <last_update_submitted_qc>June 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in Japan from September 2007 to February 2008.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into the study according to inclusion/exclusion criteria without a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series) and 12-15 months of age (toddler dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series) and 12-15 months of age (toddler dose).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="193"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series</title>
        <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>one month after 3-dose infant series (at 7 months of age)</time_frame>
        <population>Evaluable immunogenicity population had valid and determinate assay results and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series</title>
          <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity population had valid and determinate assay results and had no other major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="95.1" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" lower_limit="93.5" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="94.3" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
        <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after each dose</time_frame>
        <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2 months of age (infant series Dose 1).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 4 months of age (infant series Dose 2).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 3</title>
            <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 6 months of age (infant series Dose 3).</description>
          </group>
          <group group_id="O4">
            <title>13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 12-15 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
          <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="190"/>
                <count group_id="O4" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness - Any (n=165,156,147,143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="19.9"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Significant (n=160,152,143,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Any (n=176,173,165,163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2"/>
                    <measurement group_id="O2" value="53.8"/>
                    <measurement group_id="O3" value="53.9"/>
                    <measurement group_id="O4" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Mild (n=174,171,163,154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0"/>
                    <measurement group_id="O2" value="49.1"/>
                    <measurement group_id="O3" value="50.3"/>
                    <measurement group_id="O4" value="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Moderate (n=167,164,150,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="28.7"/>
                    <measurement group_id="O3" value="29.3"/>
                    <measurement group_id="O4" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Severe (n=160,153,143,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Any (n=186,180,171,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2"/>
                    <measurement group_id="O2" value="74.4"/>
                    <measurement group_id="O3" value="67.8"/>
                    <measurement group_id="O4" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Mild (n=183,179,162,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3"/>
                    <measurement group_id="O2" value="64.8"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Moderate (n=170,168,157,155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7"/>
                    <measurement group_id="O2" value="43.5"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Severe (n=160,153,143,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
        <description>Systemic events (fever ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after each dose</time_frame>
        <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Subjects received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2 months of age (infant series Dose 1).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Dose 2</title>
            <description>Subjects received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 4 months of age (infant series Dose 2).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 3</title>
            <description>Subjects received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 6 months of age (infant series Dose 3).</description>
          </group>
          <group group_id="O4">
            <title>13vPnC Toddler Dose</title>
            <description>Subjects received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 12-15 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
          <description>Systemic events (fever ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="190"/>
                <count group_id="O4" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥37.5°C (n=170,163,154,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9"/>
                    <measurement group_id="O2" value="33.1"/>
                    <measurement group_id="O3" value="40.3"/>
                    <measurement group_id="O4" value="50.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥38°C but ≤39°C (n=163,156,146,137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="10.3"/>
                    <measurement group_id="O4" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39°C but ≤40°C (n=161,153,143,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="2.8"/>
                    <measurement group_id="O4" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40°C (n=160,152,143,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=163,158,144,138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="16.5"/>
                    <measurement group_id="O3" value="9.7"/>
                    <measurement group_id="O4" value="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=170,166,149,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6"/>
                    <measurement group_id="O2" value="36.1"/>
                    <measurement group_id="O3" value="23.5"/>
                    <measurement group_id="O4" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=175,160,153,139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6"/>
                    <measurement group_id="O2" value="29.4"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=169,160,145,138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="15.9"/>
                    <measurement group_id="O4" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives (n=160,152,143,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication to treat symptoms (n=160,153,145,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="6.5"/>
                    <measurement group_id="O3" value="5.5"/>
                    <measurement group_id="O4" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication to prevent symptoms (n=160,153,144,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="2.1"/>
                    <measurement group_id="O4" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the 3-Dose Infant Series</title>
        <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>one mone month after 3-dose infant series (at 7 months of age)</time_frame>
        <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the 3-Dose Infant Series</title>
          <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.76" lower_limit="6.02" upper_limit="7.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" lower_limit="4.07" upper_limit="5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" lower_limit="3.03" upper_limit="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.69" lower_limit="13.26" upper_limit="16.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" lower_limit="3.27" upper_limit="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" lower_limit="4.90" upper_limit="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" lower_limit="2.21" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" lower_limit="4.48" upper_limit="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" lower_limit="2.55" upper_limit="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" lower_limit="3.42" upper_limit="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" lower_limit="3.35" upper_limit="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" lower_limit="5.19" upper_limit="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.97" lower_limit="6.25" upper_limit="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose</title>
        <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>one month after the toddler dose (at 12 - 15 months of age)</time_frame>
        <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose</title>
          <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose</title>
        <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>one month after the toddler dose (at 12-15 months of age)</time_frame>
        <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose</title>
          <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.70" lower_limit="8.43" upper_limit="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.61" lower_limit="12.52" upper_limit="17.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" lower_limit="4.00" upper_limit="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.33" lower_limit="14.49" upper_limit="18.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" lower_limit="5.34" upper_limit="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.20" lower_limit="10.37" upper_limit="14.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.55" lower_limit="5.53" upper_limit="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.85" lower_limit="8.62" upper_limit="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" lower_limit="1.83" upper_limit="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" lower_limit="6.52" upper_limit="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.03" lower_limit="9.69" upper_limit="12.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.31" lower_limit="7.39" upper_limit="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.97" lower_limit="14.07" upper_limit="18.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>13vPnC Infant Series</title>
          <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).</description>
        </group>
        <group group_id="E2">
          <title>13vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).</description>
        </group>
        <group group_id="E3">
          <title>13vPnC Toddler Dose</title>
          <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 12-15 months (toddler dose).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Local Reactions</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryostenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pectus excavatum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="115" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Vaccination site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Vessel puncture site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Any fever (≥37.5°C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Any fever (≥37.5°C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Any fever (≥37.5°C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Hives (urticaria)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Hives (urticaria)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Hives (urticaria)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Solvent sensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Omphalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Adenoviral upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lymphangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Head banging</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Fibrinous bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Eczema infantile</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Asteatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Induration(Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Induration(Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Induration(Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

